Calixar raises €1 Million

This new round will enable the French biotech company to license-out its isolation technologies for complex therapeutic targets and viral antigens

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on LinkedIn

Contact us

Secure and boost your discovery programs.

Starting from native material or recombinant systems, we succeed with all types of membrane proteins: GPCRs, Ions Channels, Transporters, Receptors and Viral Proteins.

  • Conformational antibody development
  • Vaccine development
  • High-throughput ligand screening
  • Structure-based drug discovery
  • Immunoassays
  • Deorphanization projects
  • Identification of relevant targets
  • Expression of full-length membrane proteins
  • Functional isolation and stabilization of targets

© 2020 Calixar. All rights reserved.

Linkedin-in Youtube